Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL

In vitro treatment of Idh2R140Q/NHD13 thymocytes with enasidenib, a selective inhibitor of mutant IDH2, led to a marked decrease in leukemic cell proliferation, demonstrating that Idh2R140Q/NHD13 mice could serve as a useful in vivo model for the study of early/immature T cell precursor acute lymphoid leukemia (ALL) development and therapy.